NovelStem Owns 30% of NewStem, Israel-based developer of stem cell-based diagnostic platform to identify resistance to cancer treatments, prior to treatment.

ID: 1252428484137418752

linkhttps://www.novelstem.com/ calendar_today21-04-2020 02:46:41